Cat Renal Osteodystrophy and Bone Welfare in CKD

Renal secondary hyperparathyroidism in cats with CKD causes bone demineralisation and other skeletal complications that add to the welfare burden of advanced kidney disease.

Key Facts

CKD impairs phosphorus excretion and vitamin D activation, causing secondary hyperparathyroidism
Excess parathyroid hormone demineralises bone to maintain blood calcium, causing skeletal fragility
Fibrous osteodystrophy (rubber jaw) can cause facial bone softening visible on examination in severe cases
Phosphorus restriction and phosphate binders reduce the stimulus for secondary hyperparathyroidism
Calcitriol (active vitamin D) supplementation is used in some CKD cats to reduce parathyroid hormone stimulation

Welfare Considerations

Renal osteodystrophy adds skeletal fragility and potential pain from bone demineralisation to the already considerable welfare burden of advanced CKD. Facial bone softening in severe cases can impair eating and causes visible deformity. Pathological fractures from demineralised bones are possible in severely affected cats. Phosphorus management — the cornerstone of preventing secondary hyperparathyroidism — addresses this welfare dimension alongside its primary role in slowing kidney function decline. Calcitriol supplementation under veterinary monitoring can further reduce parathyroid hormone levels. Managing CKD comprehensively, including the skeletal complications, provides better overall welfare than managing only the renal function decline.

What You Can Do

Monitor parathyroid hormone (PTH) levels in CKD cats to detect secondary hyperparathyroidism early
Implement strict phosphorus restriction and phosphate binder use to reduce PTH stimulus
Discuss calcitriol supplementation with your veterinarian for cats with elevated PTH levels
Handle CKD-affected cats carefully to avoid pathological fractures if severe bone disease is suspected